Literature DB >> 9466562

Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders.

A Takeda1, M Mallory, M Sundsmo, W Honer, L Hansen, E Masliah.   

Abstract

The precursor of the non-Abeta component of Alzheimer's disease amyloid (NACP) (also known as a-synuclein) is a presynaptic terminal molecule that accumulates in the plaques of Alzheimer's disease. Recent studies have shown that a mutation in NACP is associated with familial Parkinson's disease, and that Lewy bodies are immunoreactive with antibodies against this molecule. To clarify the patterns of accumulation and differences in abnormal compartmentalization, we studied NACP immunoreactivity using double immunolabeling and laser scanning confocal microscopy in the cortex of patients with various neurodegenerative disorders. In Lewy body variant of Alzheimer's disease, diffuse Lewy body disease, and Parkinson's disease, NACP was found to immunolabel cortical Lewy bodies, abnormal neurites, and dystrophic neurites in the plaques. Double-labeling studies showed that all three of these neuropathological structures also contained ubiquitin, synaptophysin, and neurofilament (but not tau) immunoreactivity. In contrast, neurofibrillary tangles, neuropil threads, Pick bodies, ballooned neurons, and glial tangles (most of which were tau positive) were NACP negative. These results support the view that NACP specifically accumulates in diseases related to Lewy bodies such as Lewy body variant of Alzheimer's disease, diffuse Lewy body disease, and Parkinson's disease and suggests a role for this synaptic protein in the pathogenesis of neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466562      PMCID: PMC1857971     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  The rat brain synucleins; family of proteins transiently associated with neuronal membrane.

Authors:  L Maroteaux; R H Scheller
Journal:  Brain Res Mol Brain Res       Date:  1991-10

2.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal.

Authors:  L Maroteaux; J T Campanelli; R H Scheller
Journal:  J Neurosci       Date:  1988-08       Impact factor: 6.167

3.  An antibody against phosphorylated neurofilaments identifies a subset of damaged association axons in Alzheimer's disease.

Authors:  E Masliah; M Mallory; L Hansen; M Alford; R DeTeresa; R Terry
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

4.  Identification of two distinct synucleins from human brain.

Authors:  R Jakes; M G Spillantini; M Goedert
Journal:  FEBS Lett       Date:  1994-05-23       Impact factor: 4.124

5.  A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation.

Authors:  S Nakajo; K Tsukada; K Omata; Y Nakamura; K Nakaya
Journal:  Eur J Biochem       Date:  1993-11-01

6.  Lewy bodies contain beta-amyloid precursor proteins of Alzheimer's disease.

Authors:  H Arai; V M Lee; W D Hill; B D Greenberg; J Q Trojanowski
Journal:  Brain Res       Date:  1992-07-10       Impact factor: 3.252

Review 7.  The role of synaptic proteins in the pathogenesis of disorders of the central nervous system.

Authors:  E Masliah; R Terry
Journal:  Brain Pathol       Date:  1993-01       Impact factor: 6.508

8.  Synaptophysin and chromogranin A immunoreactivities of Lewy bodies in Parkinson's disease brains.

Authors:  M Nishimura; H Tomimoto; T Suenaga; S Nakamura; Y Namba; K Ikeda; I Akiguchi; J Kimura
Journal:  Brain Res       Date:  1994-01-21       Impact factor: 3.252

9.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.

Authors:  K Uéda; H Fukushima; E Masliah; Y Xia; A Iwai; M Yoshimoto; D A Otero; J Kondo; Y Ihara; T Saitoh
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

10.  NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation.

Authors:  M Yoshimoto; A Iwai; D Kang; D A Otero; Y Xia; T Saitoh
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

View more
  116 in total

Review 1.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.

Authors:  P J Kahle; M Neumann; L Ozmen; V Müller; S Odoy; N Okamoto; H Jacobsen; T Iwatsubo; J Q Trojanowski; H Takahashi; K Wakabayashi; N Bogdanovic; P Riederer; H A Kretzschmar; C Haass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 3.  Lewy bodies and dementia.

Authors:  D Galasko
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

4.  Neuropathology in mice expressing human alpha-synuclein.

Authors:  H van der Putten; K H Wiederhold; A Probst; S Barbieri; C Mistl; S Danner; S Kauffmann; K Hofele; W P Spooren; M A Ruegg; S Lin; P Caroni; B Sommer; M Tolnay; G Bilbe
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

5.  alpha-synuclein promotes mitochondrial deficit and oxidative stress.

Authors:  L J Hsu; Y Sagara; A Arroyo; E Rockenstein; A Sisk; M Mallory; J Wong; T Takenouchi; M Hashimoto; E Masliah
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

6.  Semisynthetic, site-specific ubiquitin modification of α-synuclein reveals differential effects on aggregation.

Authors:  Franziska Meier; Tharindumala Abeywardana; Abhinav Dhall; Nicholas P Marotta; Jobin Varkey; Ralf Langen; Champak Chatterjee; Matthew R Pratt
Journal:  J Am Chem Soc       Date:  2012-03-14       Impact factor: 15.419

Review 7.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

8.  Effect of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body variant of Alzheimer disease.

Authors:  Rosa Resende; Sueli C F Marques; Elisabete Ferreiro; Isaura Simões; Catarina R Oliveira; Cláudia M F Pereira
Journal:  Neurochem Res       Date:  2013-02-07       Impact factor: 3.996

Review 9.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

10.  Intraneuronal dopamine-quinone synthesis: a review.

Authors:  D Sulzer; L Zecca
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.